Abstract:P-glycoprotein (P-gp) actively transports a wide variety of chemically diverse compounds out of cells. It is highly associated with the ADMET properties of drugs and drug candidates and, moreover, plays a major role in the multidrug resistance (MDR) phenomenon, which leads to the failure of chemotherapy in cancer treatments. Therefore, the recognition of potential P-gp substrates at the early stages of the drug discovery process is quite important. Here, we compiled an extensive data set containing 423 P-gp substrates and 399 nonsubstrates, which is the largest P-gp substrate/nonsubstrate data set yet published. Comparison of the distributions of eight important physicochemical properties for the substrates and nonsubstrates reveals that molecular weight and molecular solubility are the informative attributes differentiating P-gp substrates from nonsubstrates. Examination of the distributions of eight physicochemical properties for 735 P-gp inhibitors and 423 substrates gives the fact that inhibitors are significantly more hydrophobic than substrates while substrates tend to have more H-bond donors than inhibitors. Then, the classification models based on simple molecular properties, topological descriptors, and molecular fingerprints were developed using the naive Bayesian classification technique. The best naive Bayesian classifier yields a Matthews correlation coefficient of 0.824 and a prediction accuracy of 91.2% for the training set from a 5-fold cross-validation procedure, and a Matthews correlation coefficient of 0.667 and a prediction accuracy of 83.5% for the test set containing 200 molecules. Analysis of the important structural fragments given by the Bayesian classifier shows that the essential H-bond acceptors arranged in distinct spatial patterns and flexibility are quite essential for P-gp substrate-likeness, which affords a deeper understanding on the molecular basis of substrate/P-gp interaction. Finally, the reasons for mispredictions were discussed. It turns out that the presented classifier could be used as a reliable virtual screening tool for identifying potential substrates of P-gp.

Comparing Various in Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P‐glycoprotein (p‐gp) Transporter in Vivo

The Effects of Traditional Chinese Medicine on P-Glycoprotein–Mediated Multidrug Resistance and Approaches for Studying the Herb–P-Glycoprotein Interactions

Rapid identification of P-glycoprotein substrates and inhibitors

Investigation on Modulation of Human Cytochrome P450 and P-glycoprotein by Herb or Natural Product Using in Vivo Probe Substrate

Evaluation of Drug Interactions with P-Glycoprotein in Drug Discovery: In Vitro Assessment of the Potential for Drug-Drug Interactions with P-Glycoprotein

Combined Qsar and Molecule Docking Studies on Predicting P-Glycoprotein Inhibitors

Admet Evaluation in Drug Discovery. 13. Development of in Silico Prediction Models for P-Glycoprotein Substrates

Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery

Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors

Inhibitory Effects of Herbal Constituents on P-glycoprotein in Vitro and in Vivo: Herb-Drug Interactions Mediated Via P-gp.

ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques.

Computationally accelerated identification of P-glycoprotein inhibitors

Reliability of in Vitro and in Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics

In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions

Research progress of P-glycoprotein induction

Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes

Ginsenoside Metabolites Inhibit P-Glycoprotein in Vitro and in Situ Using Three Absorption Models

20(S)-Ginsenoside Rh2 Noncompetitively Inhibits P-Glycoprotein In Vitro And In Vivo: A Case For Herb-Drug Interactions

Application of a new MDCKII-MDR1 cell model to measure the extent of drug distribution in vitro at equilibrium for prediction of in vivo unbound brain-to-plasma drug distribution